What are regulatory submissions in drug development?

Open regulatory dossier binder on a clinical desk with stacked pharmaceutical vials and a fountain pen on official documents.

Regulatory submissions in drug development are formal applications submitted to regulatory authorities, such as the EMA or FDA, requesting approval to conduct clinical trials, manufacture, or market a medicinal product. These submissions package all the scientific, clinical, and quality evidence a company has generated to demonstrate that a drug is safe, effective, and consistently manufactured. The sections below walk through the most important questions companies have about navigating this process.

What types of regulatory submissions exist in drug development?

Several distinct types of regulatory submissions exist in drug development, each serving a different purpose and stage of the product lifecycle. The main categories include applications to begin clinical trials, applications for marketing authorisation, and post-approval submissions that maintain or update a product’s approved status.

The most common submission types include:

  • Clinical Trial Application (CTA): Required before a sponsor can begin testing a drug in human subjects. In the EU, these are submitted through the CTIS portal under the Clinical Trials Regulation (EU) No 536/2014.
  • Marketing Authorisation Application (MAA): The full dossier submitted to obtain approval to place a medicinal product on the market. In the EU, this can follow the centralised, decentralised, mutual recognition, or national procedure depending on the product and target markets.
  • Investigational New Drug Application (IND): The US equivalent of a CTA, submitted to the FDA before clinical studies begin.
  • New Drug Application (NDA) or Biologics License Application (BLA): US marketing approval applications for small molecules and biologics, respectively.
  • Variations and renewals: Post-approval submissions that update approved dossiers to reflect changes in manufacturing, labelling, clinical data, or other aspects of the product.
  • Scientific advice requests: Formal interactions with authorities, such as EMA’s Scientific Advice procedure, that help companies align their development plans before submitting a full application.

Understanding which submission type applies to your product and target market is the first strategic decision a regulatory team must make, as it shapes the entire development and evidence-generation plan.

How does the regulatory submission process work step by step?

The regulatory submission process moves through several defined phases: pre-submission planning, dossier compilation, formal submission, regulatory review, and response to questions or deficiencies. While the exact steps vary by submission type and jurisdiction, the overall flow is consistent across most major markets.

  1. Define the regulatory strategy: Identify the applicable procedure, target markets, and submission pathway. Engage with authorities early through scientific advice or pre-submission meetings where available.
  2. Generate the evidence base: Conduct the preclinical studies, clinical trials, and quality development activities needed to support the dossier. The regulatory strategy should guide what data is generated and how it is documented.
  3. Compile the dossier: Organise all data into the required format, typically the Common Technical Document (CTD) structure used globally, covering quality, non-clinical, and clinical modules.
  4. Validate and submit: Authorities perform an administrative check to confirm the dossier is complete before starting the scientific review clock.
  5. Respond to questions: Reviewers issue questions or lists of outstanding issues during the review. The applicant must respond within defined timeframes with additional data or clarifications.
  6. Receive the decision: The authority issues an approval, a refusal, or a request for further information before a final decision is made.
  7. Post-approval maintenance: Once approved, companies must submit periodic safety update reports, variations for any changes, and renewal applications as required.

What does a regulatory submission dossier contain?

A regulatory submission dossier contains comprehensive documentation covering the quality, safety, and efficacy of the medicinal product. For most major markets, this is structured according to the Common Technical Document (CTD) format, which organises information into five modules.

  • Module 1 – Administrative information: Application forms, product information (SmPC, labelling, package leaflet), and region-specific documents.
  • Module 2 – Summaries: Expert overviews and summaries of the quality, non-clinical, and clinical data, written to guide reviewers through the evidence.
  • Module 3 – Quality: Detailed documentation on the drug substance and drug product, including manufacturing processes, analytical methods, specifications, stability data, and container closure systems.
  • Module 4 – Non-clinical study reports: Pharmacology, pharmacokinetics, and toxicology studies conducted in vitro and in animal models.
  • Module 5 – Clinical study reports: All human clinical data, including bioavailability, dose-finding, efficacy, and safety studies.

The quality and completeness of each module directly affect the outcome of the review. Gaps in any section can trigger questions from reviewers or, in serious cases, lead to a refusal. Regulatory operations teams play a critical role in ensuring the dossier is internally consistent, correctly formatted, and submitted through the appropriate electronic gateway.

How long does regulatory review of a drug submission take?

The review timeline for a regulatory submission depends on the procedure, the submission type, and the complexity of the product. For a centralised MAA in the EU, the standard review clock runs 210 days, though clock stops, periods during which the applicant prepares responses to questions, can extend the total calendar time to 12 to 18 months in practice.

Key timeframes to plan around include:

  • EU centralised MAA: 210 active review days, with clock stops typically adding several months of real time.
  • FDA standard review (NDA/BLA): 12 months from the date of filing; priority review is 6 months.
  • Clinical Trial Applications (EU): 30 days for standard trials; 10 days for certain gene therapy or advanced therapy products in some cases, though timelines vary by member state and trial complexity.
  • Variations: Type IA variations can be implemented immediately (with notification), while Type II variations follow a full review cycle of up to 90 days.

Companies should build these timelines into their development plans from an early stage. Underestimating review timelines is a common cause of delayed product launches and budget overruns.

What are the most common reasons regulatory submissions get rejected?

Regulatory submissions are most commonly rejected because of insufficient clinical evidence of efficacy or safety, significant quality deficiencies in the Chemistry, Manufacturing and Controls (CMC) section, or a failure to demonstrate that the benefit-risk balance is favourable for the intended patient population. In many cases, rejections are preventable with better planning and earlier regulatory engagement.

The most frequent causes of rejection include:

  • Inadequate clinical data: Trials that were too small, too short, or used endpoints that authorities do not consider clinically meaningful.
  • CMC deficiencies: Incomplete characterisation of the drug substance or product, gaps in stability data, or manufacturing processes that are not sufficiently validated.
  • Inconsistencies across the dossier: Contradictions between modules, or data in the summaries that does not match the underlying study reports.
  • Failure to address known regulatory concerns: Ignoring guidance documents, precedents from similar products, or feedback received during scientific advice procedures.
  • Poorly written expert overviews: Module 2 summaries that fail to present the evidence persuasively or do not address known weaknesses proactively.
  • Wrong regulatory pathway: Applying under a procedure or claiming a status (such as orphan designation or biosimilar pathway) for which the product does not qualify.

Many of these issues can be avoided by seeking regulatory affairs support early in development, when there is still time to course-correct the evidence package before a submission is filed.

When should a company engage a regulatory affairs consultant for submissions?

A company should engage a regulatory affairs consultant as early as possible in the development process, ideally at the point of defining the regulatory strategy, before significant resources are committed to clinical or manufacturing activities. Early engagement helps ensure the development programme is designed to meet the evidentiary standards regulators expect.

There are specific moments where external regulatory expertise adds particular value:

  • At product concept stage: To determine the correct classification, applicable legislation, and the most efficient regulatory pathway for the target markets.
  • Before clinical trials begin: To prepare and submit the CTA and ensure the trial design will generate data that supports a future marketing application.
  • During dossier compilation: To manage the CTD structure, identify gaps, and coordinate the technical writing of Module 2 summaries.
  • When responding to regulatory questions: To interpret authority feedback accurately and prepare scientifically robust responses within the required timeframes.
  • For post-approval changes: To assess whether a change requires a variation, manage the submission, and maintain the approved dossier over the product lifecycle.

Smaller companies and those entering a new market for the first time benefit most from external support, as they often lack the in-house experience needed to navigate unfamiliar procedures. Larger organisations frequently bring in consultants to supplement internal capacity during peak submission periods or for specialised product types such as ATMPs or combination products. You can learn more about the team behind this work on our company page.

How Starodub supports your regulatory submissions

At Starodub, we provide end-to-end support for regulatory submissions across the full product lifecycle, from first-in-human trials to post-approval maintenance. Our team combines deep scientific expertise with hands-on experience across EU and global submission procedures, so we can step in at any stage of your development programme and add immediate value.

Here is what working with us looks like in practice:

  • Regulatory strategy development: We define the most efficient pathway to approval for your product, whether it is a small molecule, biologic, vaccine, or combination product.
  • Dossier preparation and management: We compile, review, and quality-check your CTD dossier across all modules, ensuring consistency and completeness before submission.
  • CTA and MAA submissions: We manage the full submission process, including formatting, gateway submission, and authority liaison.
  • Responses to regulatory questions: We interpret authority feedback and coordinate scientifically sound, timely responses that keep your review on track.
  • Variations and lifecycle management: We handle post-approval changes, renewals, and periodic safety update reports to keep your product in good standing.
  • Quality and compliance support: Through our Quality, Compliance and Operational Improvements division, we help you build the internal systems that support robust submissions from the ground up.

With over 400 completed projects and more than 300 clients supported, Starodub brings proven experience to every submission. If you are preparing for a regulatory submission or want to make sure your development programme is on the right track, get in touch with our team and we will be happy to discuss how we can help.

Related Articles

This content was generated with the help of AI and it may contain mistakes

Patrick Vronen
Management team member - Senior RA Consultant
Patrick Vronen

Let's Connect

Talk to an expert